Evidence map›Paper›PMID 40495961›Full record

ArticleFrontiers in medicine2025

The effectiveness of an oral gonadotropin-releasing hormone antagonist relugolix for retained products of conception (RPOC) formed after abortion at less than 22 weeks of gestation: a retrospective study.

Satoko Sasatsu, Yosuke Ono, Dai Miyashita, Tatsuya Yoshihara, Kota Tanaka, So Owada, Kana Makino, Akiko Nakagomi, Maki Ogi, Eriko Ogasawara and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Satoko SasatsuDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Yosuke OnoDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Dai MiyashitaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Tatsuya YoshiharaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Kota TanakaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
So OwadaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Kana MakinoDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Akiko NakagomiDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Maki OgiDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Eriko OgasawaraDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Hikaru TagayaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Hiroko FukasawaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Yasuhiko OkudaDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.
Osamu YoshinoDepartment of Obstetrics and Gynecology, University of Yamanashi, Yamanashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study investigated the effectiveness of an oral GnRH antagonist for retained products of conception (RPOC) carrying a risk of heavy bleeding. Methods: With IRB approval and patient consent, this retrospective study included 97 RPOC cases after miscarriage. Clinical courses of the GnRH antagonist group ( Results: The reduction rate in the maximum RPOC diameter after treatment initiation in GnRH antagonist group was greater compared to that in non-GnRH antagonist group [50 (0-79.7)% vs. 15.4 (0-56.9)]%, Conclusion: GnRH antagonist may be a new therapeutic candidate for RPOC.

Indexed as

GnRH antagonistmenstrual resumptionmiscarriageretained products of conceptionsurgical intervention

Identifiers

PMID40495961
PMCPMC12148917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.